Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Efficacy, Safety, & PROs From the Phase III IMbrave050 Trial - Adjuvant Atezo + Bev vs. Active Surveillance in HCC Patients With High Risk of Disease Recurrence Following Resection or Ablation"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Masatoshi Kudo
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Masatoshi Kudo
Comments 0
Login to view comments.
Click here to Login
